Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 21;100(20):e25898.
doi: 10.1097/MD.0000000000025898.

Does tranexamic acid reduce risk of mortality on patients with hemoptysis?: A protocol for systematic review and meta-analysis

Liang-Fu Chen  1   2 , Ting-Cheng Wang  1   2 , Ting-Yi Lin  1   2 , Po-Jia Pao  1   2 , Karen Chia-Wen Chu  1   2 , Chih-Hao Yang  1   2 , Jer-Hwa Chang  3   4   5 , Chin-Wang Hsu  1   2 , Chyi-Huey Bai  6 , Yuan-Pin Hsu  1   2   7
Affiliations

Does tranexamic acid reduce risk of mortality on patients with hemoptysis?: A protocol for systematic review and meta-analysis

Liang-Fu Chen et al. Medicine (Baltimore). .

Abstract

Background: Although tranexamic acid (TXA), a readily accessible antifibrinolytic agent, is widely adopted in hemorrhage scenarios, its role on mortality in patients with hemoptysis remains uncertain. New evidence is yet to be generated to evaluate the risk of mortality after using TXA in patients with hemoptysis.

Methods: PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus databases were searched from inception to May 2020. Randomized controlled trials and observational studies that evaluated the effect of TXA on patients with hemoptysis were included. Data were independently extracted by 2 reviewers and synthesized using a random-effects model.

Main results: Five studies with a total of 20,047 patients were analyzed. When compared with the control, administration of TXA was associated with a reduction in short-term mortality (risk ratio = 0.78, 95% confidence interval [CI] 0.72-0.85; I2 = 0), shorter bleeding time (mean difference = - 24.61 hours, 95% CI - 35.96 to -13.26, I2 = 0), shorter length of hospital stay (mean difference = -1.94 days, 95% CI -2.48 to -1.40, I2 = 0), and lower need for intervention (risk ratio = 0.38, 95% CI 0.16-0.87, I2 = 0) in patients with hemoptysis. Compared with control, administration of TXA did not cause increased major or minor adverse effects.

Conclusions: TXA provided benefits in terms of a lower short-term mortality rate, less bleeding time, shorter length of hospital stays, and less need for intervention in patients with hemoptysis. Use of TXA was not associated with increased adverse effects.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of article selection process.
Figure 2
Figure 2
Meta-analysis evaluating the short-term mortality rate after tranexamic acid administration.
Figure 3
Figure 3
Meta-analysis evaluating short-term mortality rate of the intravenous tranexamic acid subgroup.
See this image and copyright information in PMC

References

    1. Mondoni M, Carlucci P, Job S, et al. . Observational, multicentre study on the epidemiology of haemoptysis. Eur Respir J 2018;51: - PubMed
    1. Hirshberg B, Biran I, Glazer M, et al. . Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997;112:440–4. - PubMed
    1. Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration 2010;80:38–58. - PubMed
    1. Dweik RA, Stoller JK. Role of bronchoscopy in massive hemoptysis. Clin Chest Med 1999;20:89–105. - PubMed
    1. Abdulmalak C, Cottenet J, Beltramo G, et al. . Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. Eur Respir J 2015;46:503–11. - PubMed

MeSH terms